EGFR and cancer: Targeting OXPHOS restores the sensitivity of vemurafenib (v-Raf murine sarcoma viral oncogene homolog B (BRAF) inhibitor) - and gefitinib (Epidermal growth factor receptor (EGFR) inhibitor)-resistant cancer cells to the corresponding drugs [17].